Knoll AG, part of the German chemicals major BASF, will route all new pharmaceutical products through its wholly owned subsidiary, Knoll International Pvt Ltd. The exports of drugs and some formulations will also be routed through Knoll International, which will also own the entire range of new products. Knoll International, which was set up on January 1 this year, is yet to begin operations in India.
The DM 46.2 billion conglomerate, BASF AG has two wholly owned subsidiaries -- Knoll International Pvt Ltd and BASF Industries, while it holds 40 per cent in Knoll India and 51 per cent each in BASF (India) Ltd and Dr Beck & Co.
Knoll India, which will manufacture the new products for the German parent and Knoll International, will also market the new products for a nominal fee. Knoll International will focus on traded exports and sourcing of bulk drugs for exports, said Knoll officials. Knoll India does not have any bulk drug plant and Knoll International's bulk drug requirements will be wholly outsourced. Some formulations, which are not made by Knoll India, too, will be outsourced by Knoll International.
Knoll International will identify new markets for exports while Knoll India will continue exports to Sri Lanka, said company officials. While declining to specify the drugs which will be exported by Knoll International, company sources said they would be off-patent drugs.
Knoll India has a formulations plant at Jejuri in Gujarat and a new plant was commissioned at Verna in Goa in July last. The company sold off its bulk drug plant at Ahmednagar in Gujarat for Rs 7 crore while its facility at Sion in Mumbai was disposed off for Rs 66 crore.
Knoll India has two wholly owned subsidiaries, Lenbrook Pharmaceuticals and Beem Healthcare, which are looking after exports and marketing, respectively. Its another subsidiary, Valencia Pharmaceuticals, is yet to commence operations.
The three subsidiaries are expected to involve in marketing of Knoll International's products.
